HNF1A and Wilson disease: In detail, WD increased the HNF1-α protein levels by 130.0 ± 20.88% (p < 0.01), while RYR augmented the HNF1-α levels by 165.5 ± 5.87% (p < 0.001), and MOMAST® diminished its levels by 27.68 ± 7.25%, compared with the SD group (Figure 9B).